PTGS1 and colorectal adenoma: In phase IIb/III clinical trials, DFMO combined with sulindac, a nonselective inhibitor of cyclooxygenase-1(COX-1) and COX-2, effectively reduced the numbers of ectopic colorectal adenomas in individuals with histories of adenoma [48].